Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone impact on sugammadex reversal
NCT02562417Phase 4Withdrawn
- Sponsor
- Lausanne University Hospital
- Start
- Jun 2016
- Primary completion
- May 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, triple-blind trial of dexamethasone in neuromuscular blockade (NMB) (2 arms), sponsored by Lausanne University Hospital. Primary endpoint: Mean recovery time for T4/T1 ratio > 90% after sugammadex administration. Planned start Jun 2016; status: withdrawn.
02
Drugs
dexamethasone
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02562417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562417.